For your convenience, we are providing a partial list of laboratories in the U.S. that perform IV BUSULFEX Pharmacokinetic Testing and Therapeutic Drug Monitoring.
Otsuka America Pharmaceutical, Inc. does not screen or endorse these laboratories.
Commercial Laboratories that Perform Testing and Analysis
Pharmacokinetics Laboratory
Seattle Cancer Care Alliance
825 Eastlake Avenue East, G7405
Seattle, WA 98109
Contact: Matthew Pawlikowski
Phone: 206-288-7389
Fax: 206-288-7397
E-mail before June 1, 2009: busulfan@fhcrc.org
E-mail After June 1, 2009: PKLab@seattlecca.org
University of Pennsylvania Medical Center
Department of Pathology & Laboratory Medicine
Toxicology Laboratory
Hospital of the University of Pennsylvania
3400 Spruce Street, 7 Maloney Building
Philadelphia, PA 19104
Contact: Leslie Shaw, PhD
Phone: 215-662-6575
Fax: 215-662-7529
E-mail: shawlmj@mail.med.upenn.edu
Mayo Clinic
Drug/Toxicology Laboratory
Dept of Laboratory Medicine and Pathology
200 1st ST SW, Hilton Bldg 760
Rochester, MN 55905
Contact: Loralie Langman
Phone: 507-284-8408
E-mail: Langman.loralie@mayo.edu
Commercial Laboratories that Perform Testing Only
Emory Medical Laboratories
1364 Clifton Road NE, Room F-126
Atlanta, GA 30322
Contact: Tom Tuten
Phone: 404 712-4771
Voice mail: 404-712-5881
E-mail: thomas.tuten@emoryhealthcare.org
Quest Diagnostics Incorporated
1901 Sulphur Spring Road
Baltimore, MD 21227
Contacts: Larry Hirsch
Phone: 410-536-1622
Emily Wagner
Phone: 410-536-1526
The only FDA-approved agent for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation
for chronic myelogenous leukemia (CML)
WARNING: BUSULFEX® (busulfan) Injection is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. It should be administered under the supervision of a qualified physician who is experienced in allogeneic hematopoietic stem cell transplantation, the use of cancer chemotherapeutic drugs, and the management of patients with severe pancytopenia. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available. SEE "WARNINGS" SECTION OF FULL PRESCRIBING INFORMATION FOR INFORMATION REGARDING BUSULFAN-INDUCED PANCYTOPENIA IN HUMANS.
Important Safety Information At the recommended dosage, IV BUSULFEX® (busulfan) produced profound myelosuppression in all patients (ie, severe granulocytopenia, thrombocytopenia, anemia, or a combination thereof). Frequent complete blood counts should be monitored
during treatment and until recovery. Hepatic veno-occlusive disease was diagnosed in 5/61 patients and was fatal in 2/5 cases. Anticonvulsant prophylactic therapy should be administered prior to treatment. Caution should be exercised in patients with a history of seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs. Bronchopulmonary dysplasia with pulmonary fibrosis is a rare but serious condition following chronic busulfan therapy. Women of childbearing potential should be advised to avoid becoming pregnant as busulfan may cause fetal harm.
The most common nonhematologic adverse events were nausea (92% mild or moderate, 7% severe), stomatitis (71% grade 1-2, 26% grade 3-4), and vomiting (95% mild or moderate), anorexia (64% mild or moderate, 21% severe), diarrhea (75% mild or moderate, 5% grade 3-4), insomnia (83% mild or moderate, 1% severe), and fever (78% mild or moderate, 3% life-threatening).
Please see Full Prescribing Information.
